epidermal growth factor receptor (EGFR) mutation in tumor tissue and peripheral blood can predict the response to EGFR tyrosine kinase inhibitor (TKI) in non-small cell lung cancer (NSCLC). However, the heterogeneity of the sample sources makes it difficult to evaluate the detecting methodologies. The goal of this study is to compare different methods for analyzing EGFR mutation in blood and tumor tissue.
No special preparation is needed for EGFR Amplification Enzyme Immunoassay. Inform your doctor if you are on any medications or have any underlying medical conditions or allergies before undergoing EGFR Amplification Enzyme Immunoassay. Your doctor depending on your condition will give specific instructions.
|UNISEX||All age groups||Amplification indicates positive test|